ResultsIQ

ResultsIQ › Latest results › Medplus Health Services Limited

Medplus Health Services Limited Q2 FY27 results deck summary

NSE: MEDPLUS · BSE: 543427

Results deck of 27 Oct 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹20,371.1m, up 21.3% yoy (Q2 FY26: ₹16,793.3m) and 8.4% qoq (Q1 FY27: ₹18,796.0m).

Key takeaways

  1. Revenue growth Q2 FY27 revenue ₹20,371.1m, up 21.3% yoy (Q2 FY26: ₹16,793.3m) and 8.4% qoq (Q1 FY27: ₹18,796.0m).
  2. Operating EBITDA Q2 FY27 operating EBITDA ₹981.1m at 4.8% margin, up 10.7% yoy (Q2 FY26: ₹886.5m) and 50.7% qoq.
  3. Gross margin Gross margin at 25.1% was lower by 110 bps yoy, with private label down 0.6% over Q2 FY26.

Original filing on BSE

Medplus Health Services Limited Q2 FY27 results

As filed: Revenue ₹2,037 cr (+21% year on year), EBITDA ₹170 cr (+13% year on year), PAT ₹56.1 cr (0% year on year), EBITDA margin 8.4% (−59 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹1,880 cr (+22% year on year), EBITDA ₹133 cr (+2% year on year), PAT ₹33.2 cr (−21% year on year), EBITDA margin 7.1% (−140 bps). Score 25 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 140 bps year on year. Other income 47% of PBT. Consolidated profit -21% but standalone +25%. Profit fell 48% from last quarter. Share price after the results: −17.3% in 30 days (Nifty 500: +0.7%).
  • Q4 FY26: Revenue ₹1,864 cr (+23% year on year), EBITDA ₹169 cr (+24% year on year), PAT ₹64.0 cr (+25% year on year), EBITDA margin 9.1% (+7 bps). Score 57 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin was flat year on year. Other income 26% of PBT. Profit rose ₹13.0 cr on a year ago, against ₹17.0 cr the year before. Share price after the results: −7.3% in 30 days (Nifty 500: +2.5%).
  • Q3 FY26: Revenue ₹1,806 cr (+16% year on year), EBITDA ₹159 cr (+20% year on year), PAT ₹57.8 cr (+26% year on year), EBITDA margin 8.8% (+33 bps). Score 43 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin rose 33 bps year on year. Share price after the results: +3.1% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹1,679 cr (+7% year on year), EBITDA ₹150 cr (+21% year on year), PAT ₹56.0 cr (+44% year on year), EBITDA margin 8.9% (+107 bps). Score 30 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 107 bps year on year. Share price after the results: +6.0% in 28 days (Nifty 500: +0.9%).
  • Q1 FY26: Revenue ₹1,543 cr (+4% year on year), EBITDA ₹131 cr (+39% year on year), PAT ₹42.0 cr (+200% year on year), EBITDA margin 8.5% (+218 bps). Score 53 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was above it. EBITDA margin rose 218 bps year on year. Other income 28% of PBT. Profit fell 18% from last quarter. Profit rose ₹28.0 cr on a year ago, more than the ₹10.0 cr it added the year before. Share price after the results: −9.0% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹1,510 cr (+1% year on year), EBITDA ₹136 cr (+28% year on year), PAT ₹51.0 cr (+50% year on year), EBITDA margin 9.0% (+190 bps). Score 45 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 190 bps year on year. Other income 26% of PBT. Revenue fell 3% from last quarter. Revenue rose ₹19.0 cr on a year ago, against ₹238 cr the year before. Share price after the results: −4.9% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹1,561 cr (+8% year on year), EBITDA ₹132 cr (+43% year on year), PAT ₹46.0 cr (+229% year on year), EBITDA margin 8.5% (+207 bps). Score 76 of 100, Above trend. EBITDA margin rose 207 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Medplus Health Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.